Flmodafinil (CRL-40,940) – Solution, 1500mg (50mg/mL)

Flmodafinil (CRL-40,940) – Solution, 1500mg (50mg/mL)

This premium laboratory-grade research compound is supplied as a ready-to-use analytical solution (50mg/mL in PEG 400), engineered for modern scientific investigations requiring precise eugeroic (wakefulness-promoting) pharmacology. Flmodafinil (bisfluoromodafinil) is a fluorinated modafinil analog demonstrating similar but somewhat more powerful effects than modafinil, functioning as a selective atypical dopamine reuptake inhibitor, making it a valuable tool for in vitro/in vivo modeling of dopaminergic pathways, narcolepsy research, ADHD studies, chronic fatigue syndrome investigation, and cognitive enhancement research.

All domestic orders ship directly from primary United States production facilities, ensuring rapid delivery to all 50 U.S. states. International orders to the UK and continental Europe are fulfilled through our dedicated United Kingdom shipping hub, enabling seamless, efficient customs clearance across European borders without delay.

• Lot-coded containers with publicly accessible third-party HPLC/LC-MS lab reports verifying specification ≥99% purity for absolute transparency

• Formulation completely free of adulterants, excipients, and stabilizers to guarantee raw chemical purity in solution

• Strategic over-weighing inside the vial compensates for natural adhesion loss during laboratory transfer and pipetting

• Packaging engineering utilizes a light-protected glass vial with chemically inert tamper-proof seal to maintain solution stability during transit

Technical Specifications & Chemical Profile

Research Applications & Storage Protocols

Dopamine Reuptake Inhibitor (DRI) Eugeroic Profile

Flmodafinil (CRL-40,940, bisfluoromodafinil, lauflumide) functions as a selective atypical dopamine reuptake inhibitor, representing a fluorinated modafinil analog with wakefulness-promoting eugeroic activity and psychotonic classification. As a weak dopamine reuptake inhibitor, flmodafinil has been investigated for treatment of chronic fatigue syndrome, idiopathic hypersomnia, narcolepsy, ADHD, and Alzheimer’s disease, with preclinical development continuing for chronic fatigue syndrome as of January 2024. The compound modulates dopamine and norepinephrine levels in the brain, promoting wakefulness and improved cognitive function, demonstrating similar but somewhat more powerful effects than modafinil, making it valuable for investigators studying dopaminergic neurotransmission, neural activity patterns, wakefulness mechanisms, cognitive enhancement pathways, fatigue reduction, and comparative pharmacology of modafinil analogs in in vitro and in vivo experimental models.

Handling & Storage Guidelines

• Long-Term Storage: Store at room temperature in a tightly sealed container, away from heat, light, and moisture

• Solubility: Poorly soluble in water; poorly soluble in ethanol; soluble to 1 mg/mL in isopropanol; supplied pre-dissolved in PEG 400 at 50mg/mL

• Appearance: Clear, colorless liquid in light-protected glass vial

Global Logistics & Order Fulfillment

We proudly support scientific advancement across all 50 U.S. states and throughout Europe. Customers can seamlessly toggle their preferred currency between USD and EUR using the currency switcher located on the left-hand side of our website. All shipments are securely packaged to withstand international transit without compromising structural or chemical stability.

Laboratory Use Only Disclaimer

This material is sold strictly for laboratory research and development use only. It is not approved for human consumption, nor for medical, veterinary, or household applications. All purchases are governed by our standard Terms & Conditions. Please review them carefully before placing your order.